secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0001213900-25-032135
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 4.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma reports 2024 revenue up 234%, EPS improves 77%, but restates FY2023 financials
--------------------------------------------------------------------------------

- Revenue $509,589 (+234% YoY); net loss narrowed to $4.90M; EPS improved 77% to ($0.42).
- Operating expenses cut 21% to $5.21M; SG&A down 58%, R&D down 83%.
- Remaining milestone payments potential of $18.3M from licensing partners.
- Board concludes FY2023 financials should no longer be relied upon due to errors in share-based payments, interest, non-controlling interest.
- Material weakness in internal controls over financial reporting identified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390025032135/0001213900-25-032135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390025032135/ea0238372-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-032135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer